novo nordisk obesity drug - Search News

Novo Nordisk Shares Fall

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

The Wall Street Journal on MSN · 1d

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an earlier study recorded 22.7%.

Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that fell short of investors’ expectations.

Roche, obesity and Zealand

Reuters on MSN · 29m

Roche secures Zealand obesity drug candidate for up to $5.3 billion

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.

Bloomberg · 1h

Roche, Zealand Pharma in $5.3 Billion Pact for Obesity Drugs

Roche Holding AG licensed a new weight-loss drug from Zealand Pharma A/S for as much as $5.3 billion, bolstering the Swiss drugmaker’s effort to get into a hot market dominated by Novo Nordisk A/S and Eli Lilly & Co.

Roche partners with Zealand Pharma to push forward obesity drug

Roche partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion upfront, expanding its obesity pipeline.

13m

Compound versions of some weight loss drugs to be restricted

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Pharmaceutical Technology13h

Viking strikes $150m deal to secure supply of obesity drug

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results